“The area that is of great interest is DNA damage repair (DDR) gene targeting and strategies in pancreatic cancer, both clinically and preclinically, and being able to understand the biology and signals that we can build upon,” said O’Reilly, associate director for clinical research at Memorial Sloan Kettering Cancer Center. Read more . . .
Conducting germline testing on patients with pancreatic cancer, and potentially treating them with PARP inhibitors in the maintenance setting, has become a novel approach in the paradigm, according to Eileen O’Reilly, MD.